TEM's Genomics unit is expected to report strong growth for the first quarter, banking on continued unit growth pick-up.

Tempus AI, Inc. TEM is scheduled to report first ... (Find the latest EPS estimates and surprises on Zacks Earnings Calendar). The Zacks Consensus Estimate for revenues is currently pegged at ...

Reports are filed within 45 days after calendar quarter end with the vast majority of updates occurring near the 45th day of the quarter. Nasdaq provides the ownership stake information in a ...

Tempus AI shares rose after a Q1 beat, as an analyst highlighted its AI-driven growth, expanding pharma deals, and $1B+ ...

Tempus AI reports first-quarter revenue of $255.74 million, beating estimates of $248.13 million. The AI-focused precision ...

Lefkofsky announced a three-year, $200 million data and modeling license agreement with AstraZeneca and Pathos to build the world’s largest foundation model in oncology. This agreement increased ...

CEO Eric Lefkofsky highlighted a record quarter for Tempus, with quarterly revenue increasing 75.4% year-over-year to $255.7 million. Genomics revenue grew 89% year-over-year to $193.8 million ...

Tempus enters earnings with strong tailwinds but elevated scrutiny. The stock has surged over 80% in the past six months, and analysts have maintained tight but bullish targets — averaging $61. ...

CHICAGO (AP) — CHICAGO (AP) — Tempus AI Inc. (TEM) on Tuesday reported a loss of $68 million in its first quarter. On a per-share basis, the Chicago-based company said it had a loss of 40 cents.